Commercial framework positions the AirJoule™ platform technology to deliver pure distilled water using waste heat at unprecedented industrial scaleRONAN, Mont., Dec. 02, 2025 (GLOBE NEWSWIRE) -- AirJoule Technologies Corporation (NASDAQ: AIRJ) (“AirJoule Technologies” or “AIRJ”), today identified Nexus Data Centers (“Nexus”) as the AI hyperscale data center developer previously referenced in its June 2025 memorandum of understanding (“MOU”) press release and is now accelerating the first deployment of AirJo ...

DURHAM, N.C., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs (“Pelthos”), today announced that Pelthos’ CEO Scott Plesha will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference (the “Conference”) on December 4, 2025 at 9:30 a.m. Eastern Time at The Lotte New York Palace located at 455 Madison Avenue, New York, NY 10022. Instit ...

Teledyne DALSA's Xtium3 Teledyne’s Xtium3 PCIe Gen4 frame grabber series MONTREAL, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Teledyne DALSA, a Teledyne Technologies [NYSE: TDY] company, announces the release of the Xtium™3 PCIe Gen4 family, a next-generation frame grabber engineered to deliver maximum sustained throughput and ready-to-use image data for high-performance industrial applications. Building on the proven Xtium2 platform, the first model, Xtium3-CLHS PX8 supports the Camera Link HS® (CLHS) standard ...

Proven commercial leader with 20+ years of experience driving revenue growth and market adoption for early-stage and high-growth MedTech companiesStrong track record of launching breakthrough technologies across spine, neurosurgery and pain managementStrengthens Aclarion’s commercial execution as the Company expands adoption and payer engagement across the Eastern U.S. BROOMFIELD, Colo., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare techn ...

VANCOUVER, Wash., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Barrett Business Services, Inc. (BBSI) (NASDAQ: BBSI), a leading provider of business management solutions and one of the largest professional employer organizations (PEO) in the U.S., is proud to announce that for the fifth year in a row, the company has been Certified™ by Great Place To Work®. This prestigious award is based entirely on what current employees say about their experience working at BBSI. “We are honored to be recognized as a Great Place To ...

SINGAPORE, Dec. 02, 2025 (GLOBE NEWSWIRE) -- GCL Global Holdings Ltd (Nasdaq: GCL) (“GCL” or the “Company”), a leading provider of games and entertainment, today announced that the Company will be participating in the upcoming Benchmark Discovery One-on-One Conference in New York City. Benchmark’s 14th Annual Discovery One-on-One Conference 1x1 in-person meetings Who: Sebastian Toke, Group CEO When: December 4, 2025, 8:45pm – 3:40pm Eastern Where: New York Athletic Club in New York City About GCL Global Ho ...

VANCOUVER, British Columbia, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Refined Energy Corp. (CSE: RUU | OTC: RRUUF | FRA: CWA0) ("Refined” or the "Company") is pleased to announce the appointment of veteran uranium explorer Ken Wheatley to its Board of Directors. Mr. Wheatley is a Professional Geoscientist registered with the Association of Professional Engineers and Geoscientists of Saskatchewan and brings more than 44 years of uranium exploration expertise across Canada’s premier mining jurisdictions. Since begin ...

TORONTO, Dec. 02, 2025 (GLOBE NEWSWIRE) -- DPM Metals Inc. (TSX: DPM, ASX: DPM) (ARBN: 689370894) (“DPM” or “the Company”) is pleased to announce initial Mineral Resource Estimates (“MRE”) for the Dumitru Potok, Rakita North and Frasen prospects in eastern Serbia, all located within one to two kilometres of planned Čoka Rakita infrastructure. Highlights Establishes a potential district scale platform, with a combined Inferred MRE of 84.4 million tonnes at a grade of 0.97 g/t gold and 1.02% copper for 2.6 mi ...

-- New data published in Pain Physician shows significant improvement in functional outcomes with iovera° ---- Fewer iovera° patients required additional spine injections after 180 days ---- No treatment-related adverse events were reported -- BRISBANE, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced results from a randomized 30-patient ...

Core Insights - Clearmind Medicine Inc. has enrolled and dosed the first participant in its Phase I/IIa clinical trial for Alcohol Use Disorder (AUD) with its proprietary drug candidate CMND-100 at Hadassah-University Medical Center in Jerusalem, marking a significant milestone in the trial [1][2][3] Company Overview - Clearmind is a clinical-stage biotech company focused on developing novel neuroplastogen-derived therapeutics to address major under-treated health issues, including AUD [1][4] - The company aims to research and commercialize psychedelic-based compounds as regulated medicines, foods, or supplements [4] Clinical Trial Details - The trial at Hadassah-University Medical Center is led by Prof. Joseph Caraco and evaluates the safety, tolerability, pharmacokinetics, and preliminary efficacy of CMND-100 in AUD patients [2] - Recent positive results from the first cohort and a unanimous recommendation from the Data and Safety Monitoring Board support the continuation of the trial [2] Intellectual Property - Clearmind's intellectual portfolio includes nineteen patent families with 31 granted patents, and the company plans to seek additional patents as warranted [5]